Article Information
History
- July 31, 2024.
Article Versions
- Version 1 (January 22, 2024 - 14:07).
- Version 2 (April 4, 2024 - 12:48).
- You are viewing Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Alexander Preissa,#,*,
- Abhishek Bhatiab,*,
- Leyna V. Aragonc,
- John M. Barattab,
- Monika Baskaranb,
- Frank Blancerod,
- M. Daniel Brannocka,
- Robert F. Chewa,
- Iván Díaze,
- Megan Fitzgeraldf,
- Elizabeth P. Kellyb,
- Andrea Zhoug,
- Thomas W. Cartoni,
- Christopher G. Chutei,
- Melissa Haendelb,
- Richard Moffittj and
- Emily Pfaffb
- N3C Consortium and the RECOVER EHR Cohort
- aRTI International, Durham, NC, USA
- bUniversity of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- cUniversity of New Mexico, Albuquerque, NM, USA
- dRECOVER Community Representative
- eNew York University Grossman School of Medicine, New York, NY, USA
- fPatient Led Research Collaborative
- gUniversity of Virginia, Charlottesville, VA, USA
- hTulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA
- iJohns Hopkins University School of Medicine, Public Health, and Nursing, Baltimore, MD, USA
- jEmory University School of Medicine, Atlanta, GA, USA
- ↵#Corresponding Author:
Alexander Preiss, apreiss{at}rti.org
↵* Authors contributed equally to this work
Posted July 31, 2024.
Effect of Paxlovid Treatment During Acute COVID-19 on Long COVID Onset: An EHR-Based Target Trial Emulation from the N3C and RECOVER Consortia
